New
HealthMore in Health →
Phase 3 Trial Finds Benralizumab Cuts Flare Risk in Rare Eosinophilic Disease
A randomized phase 3 study reports that benralizumab significantly reduced the risk of first flare in patients with FIP1L1::PDGFRA-negative hypereosinophilic syndrome while showing a safety profile consistent with prior用
Key Takeaways
- The NATRON phase 3 study enrolled 133 patients with FIP1L1::PDGFRA-negative HES.
- Benralizumab reduced the risk of first flare versus placebo with a hazard ratio of 0.35.
DE
DT Editorial AI··via nature.com